Peptide-based treatment with mesoporous silica particles for mycobacterial infections
Tuberculosis (TB) and other mycobacterial infections have become more difficult to treat since the strains need to be screened for resistance. Furthermore, the half-year long treatment time could harm hepatocytes as a side effect of the treatment. This calls for discovery of new compounds for a successful treatment. One such promising peptide was recently discovered and called NZX. In this study
